Clinical trials
Advanced or Metastatic Non-small Cell Lung Cancer clinical trials
Below are recruiting advanced or metastatic non-small cell lung cancer clinical trials, each written for real people, not researchers. We’re tracking 5,550 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07309185RecruitingPhase 2
Adebrelimab, famitinib, and irinotecan for advanced stomach cancer
This trial tests a combination of three drugs (adebrelimab, famitinib, and irinotecan) for people with advanced stomach or gastroesophageal junction cancer that got worse after first-line treatment. It may offer a new option if you have already tried standard therapy.
Jinan, ShandongAges 18–75 - NCT07311408RecruitingPhase 2
New drug combo for stomach cancer after immunotherapy
This trial tests a combination of new drugs (SHR-1701, Rivoceranib, and possibly SHR-2554) for people with advanced stomach cancer whose disease has continued to grow after immunotherapy. It aims to find a better treatment option for those who have not had success with standard therapy.
Shenyang, LiaoningAges 18 years+ - NCT07289997RecruitingPhase 2
Combination therapy for advanced AFP-producing gastric cancer
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus a targeted therapy (apatinib) and a chemotherapy drug (irinotecan hydrochloride) for people with a rare type of advanced stomach cancer called AFP-producing gastric cancer. It is for patients whose cancer did not respond to previous immunotherapy combined with chemotherapy.
Shijiazhuang, HebeiAges 18 years+ - NCT07287995RecruitingPhase 1/Phase 2
Study of ASP2998 alone or with other therapies for solid tumors
This trial tests a new drug, ASP2998, given alone or with standard cancer treatments for people with advanced solid tumors, including certain types of lung, bladder, stomach, and breast cancers. The goal is to see if ASP2998 can help when other treatments have stopped working or are not an option.
Hackensack, New JerseyAges 18 years+ - NCT07292038RecruitingPhase 1
Testing NM6603 in advanced solid tumors
This study tests an experimental oral drug called NM6603 in people with advanced solid tumors, especially colorectal cancer or triple-negative breast cancer. It aims to find a safe dose and see how the drug works in the body.
Xiamen, FujianAges 18–75 - NCT07295821RecruitingPhase 2
Osimertinib for stage III lung cancer patients who can't have chemo
This trial tests a targeted therapy pill (osimertinib) combined with radiation for people with a specific type of stage III lung cancer (EGFR mutation-positive) who cannot receive chemotherapy. The goal is to see if this treatment can shrink or control the cancer.
BeijingAges 18 years+ - NCT07283367RecruitingPhase 1/Phase 2
New drug combo for advanced colorectal cancer
This trial tests a new combination of targeted therapies for people with advanced colorectal cancer that has a certain genetic pattern (non-MSI-H, no BRAF V600E mutation). It aims to see if the combination can shrink tumors or slow the cancer's growth.
GuangzhouAges 18 years+ - NCT07284121Recruiting
Patient satisfaction and safety of Atezolizumab in routine care
This study tracks how well Atezolizumab (Tecentriq) works for people with certain lung or liver cancers in everyday medical practice. It helps doctors understand if patients are satisfied with their treatment and how it affects their quality of life.
KremsAges 18 years+ - NCT07279428RecruitingPhase 1
Study of BL-M24D1 for advanced digestive and other solid tumors
This trial tests a new drug, BL-M24D1, in people with advanced or metastatic digestive tract cancers or other solid tumors that have not responded to standard treatments. The goal is to see if it is safe and effective.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07281326RecruitingPhase 1
A study of AK138D1 for advanced solid tumors
This trial tests a new drug called AK138D1 for people with advanced solid tumors. It aims to see if the drug is safe and how well it works, especially for tumors that haven't been treated with HER3-targeted therapy before.
Harbin, HeilongjiangAges 18–75 - NCT07282262RecruitingPhase 2
Ivosidenib for advanced bile duct cancer with IDH1 mutation
This trial tests the drug Ivosidenib for people with advanced bile duct cancer that has a specific genetic change called an IDH1 mutation. It may be an option if you haven't had chemotherapy yet or if your cancer returned more than 6 months after surgery.
BeijingAges 18–80 - NCT07285850RecruitingPhase 2/Phase 3
Sequential treatment for advanced liver cancer with fatty liver
This trial tests a combination of two medications, bevacizumab and atezolizumab, given one after the other to treat advanced liver cancer that cannot be surgically removed. It is specifically for people whose liver cancer is linked to a fatty liver condition (MASLD). The goal is to see if this approach helps shrink tumors or control the disease.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06823427RecruitingPhase 2
9MW2821 with or without immunotherapy for advanced urothelial cancer
This trial tests a combination of an investigational drug (9MW2821) with an immunotherapy (toripalimab) against 9MW2821 alone for people with advanced urothelial cancer who have not yet received any systemic treatment. The goal is to see if the combination works better than the single drug.
Changsha, HunanAges 18–80 - NCT07272382Recruiting
Omega-3 supplements with immunotherapy for advanced esophageal cancer
This trial tests whether adding omega-3 fatty acid supplements to a PD-1 inhibitor (a type of immunotherapy) can help control advanced esophageal cancer. It is for people whose cancer has spread or returned, and who have not already failed a similar immunotherapy.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07269626RecruitingPhase 2
PULSAR therapy for pancreatic cancer
This trial tests whether adding a special type of radiation therapy (PULSAR) to standard chemotherapy can help control pancreatic cancer that has not spread far. It is for people who have already completed a few rounds of chemo without their cancer growing.
Seoul, Select Province/StateAges 19 years+ - NCT06883409Recruiting
Laparoscopic surgery for advanced ovarian cancer after chemo
This trial tests if laparoscopic surgery after 3-4 cycles of chemotherapy can help people with advanced epithelial ovarian cancer. It's for those whose tumors have shrunk enough after chemo and who are healthy enough for surgery.
México, TlalpanAges 18–80 - NCT07265921RecruitingPhase 1
Study of SIM0609 for advanced solid tumors
This trial tests an investigational new drug, SIM0609, for people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see early signs that it might help slow or shrink tumors.
BeijingAges 18 years+ - NCT07266298RecruitingPhase 1
T-cell therapy for advanced solid tumors
This trial tests a new therapy using your own immune cells, engineered to recognize and attack cancer cells. It is for people with advanced solid tumors who have no other standard treatment options.
Beijing, Beijing MunicipalityAges 18–75 - NCT07264075RecruitingPhase 3
Ivonescimab with or without ligufalimab vs pembrolizumab for head and neck cancer
This trial tests a new immunotherapy combination (ivonescimab alone or with ligufalimab) against the standard immunotherapy pembrolizumab (Keytruda) for people with head and neck cancer that has come back or spread. It may be an option if you have not had any prior immunotherapy and your tumor is PD-L1 positive.
Le HavreAges 18–80 - NCT07252479RecruitingPhase 1
Testing a new RAS inhibitor for advanced solid tumors
This trial is testing a new oral medication (AN9025) for people with advanced solid tumors that have a RAS mutation, such as pancreatic, colorectal, lung, or melanoma. It aims to see if the drug can shrink tumors or slow their growth when other treatments have stopped working.
Orlando, FloridaAges 18 years+ - NCT07241663Recruiting
Surgery for locally advanced pancreatic cancer
This trial is testing whether surgery can help people with a certain type of pancreatic cancer that is locally advanced but not yet spread. You may join if your cancer has shrunk or stayed stable after at least 4 months of chemotherapy and your medical team thinks surgery is possible.
PadovaAges 18 years+ - NCT06620848RecruitingPhase 2
A trial of HRS-4642 alone or with adebrelimab for advanced bile duct cancer
This trial tests a new drug, HRS-4642, either by itself or combined with another drug called adebrelimab, for people whose advanced bile duct cancer has come back or gotten worse after standard treatment. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07235202RecruitingPhase 1/Phase 2
MR001 plus chemo for advanced pancreatic cancer after first treatment
This trial tests a new drug, MR001, combined with chemotherapy for people whose pancreatic cancer has spread and no longer responds to their first treatment. It aims to see if this combination can help shrink tumors or slow the disease.
Beijing, Beijing MunicipalityAges 18–75 - NCT07232407RecruitingPhase 1
Study of a radioactive drug for advanced solid tumors
This trial tests a new radioactive drug (Lutetium-177 BL-ARC001) for people with advanced solid tumors, including stomach, bowel, and other cancers. It aims to see if the treatment is safe and how well it works.
Chengdu, SichuanAges 18 years+
Hear when a new Advanced or Metastatic Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced or metastatic non-small cell lung cancer?
- Yes. Clin2 currently lists 5,550 recruiting advanced or metastatic non-small cell lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced or metastatic non-small cell lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced or metastatic non-small cell lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Metastatic Non-squamous Non Small Cell Lung Cancer
- Advanced Non-squamous Non-small-cell Lung Cancer
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer Metastatic
- Non Small Cell Lung Cancer
- Non-squamous Non-small Cell Lung Cancer
- Locally Advanced Non-Small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.